Skip to main content
. 2019 Dec 9;11(12):1981. doi: 10.3390/cancers11121981

Figure 5.

Figure 5

B-raf V600E expression correlated with patient survival and tumor phenotype. (A) Overall survival (OS) of malignant melanoma patients according to B-raf V600E mutation levels (log-rank p = 0.001, Breslow p = 0.002 and Tarone Ware p = 0.001). (B) Histological images of mutation-positive metastatic melanoma samples: (a and b) tumors MM114 and MM111 with high expression of the B-raf V600E mutated protein; and tumor (c and d) tumors MM147 and MM120 with low expression of the B-raf V600E mutated protein. For all images the magnification and scale were 10× and 50 µm, respectively. (C) Hierarchical clustering heat map of 697 differentially expressed proteins between the two groups of mutation-positive metastatic melanomas. (D) PCA of the two groups of mutation-positive metastatic melanomas based on the differentially expressed proteins. Tumor samples from each group are highlighted in common colors: high B-raf V600E expression (V600E_H, green), low B-raf V600E expression (V600E_L, yellow).